# FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer

> **NCT03161574** · PHASE2 · WITHDRAWN · sponsor: **Guangxi Medical University**

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** FOLFOXIRI

## Key facts

- **NCT ID:** NCT03161574
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-08-11
- **Primary completion:** 2019-12-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants were recruited
- **Last updated:** 2019-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03161574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03161574, "FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03161574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*